| The proinflammatory CD14+ CD16+ DR++ monocytes are a major source of TNF KU Belge, F Dayyani, A Horelt, M Siedlar, M Frankenberger, ... The Journal of Immunology 168 (7), 3536-3542, 2002 | 1197 | 2002 |
| Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) F Dayyani, CJ Etzel, M Liu, CH Ho, SM Lippman, AS Tsao Head & neck oncology 2, 1-11, 2010 | 704 | 2010 |
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma AX Zhu, AR Abbas, MR De Galarreta, Y Guan, S Lu, H Koeppen, W Zhang, ... Nature medicine 28 (8), 1599-1611, 2022 | 361 | 2022 |
| Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents M Mao, F Tian, JM Mariadason, CC Tsao, R Lemos Jr, F Dayyani, ... Clinical cancer research 19 (3), 657-667, 2013 | 345 | 2013 |
| Selective mobilization of CD14+ CD16+ monocytes by exercise B Steppich, F Dayyani, R Gruber, R Lorenz, M Mack, ... American Journal of Physiology-Cell Physiology, 2000 | 260 | 2000 |
| Steps in prostate cancer progression that lead to bone metastasis JK Jin, F Dayyani, GE Gallick International journal of cancer 128 (11), 2545-2561, 2011 | 247 | 2011 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 229 | 2023 |
| Cause of death in patients with lower‐risk myelodysplastic syndrome F Dayyani, AP Conley, SS Strom, W Stevenson, JE Cortes, G Borthakur, ... Cancer 116 (9), 2174-2179, 2010 | 205 | 2010 |
| Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis F Dayyani, BA Czerniak, K Sircar, MF Munsell, RE Millikan, CP Dinney, ... The Journal of urology 189 (5), 1656-1661, 2013 | 185 | 2013 |
| Novel therapies for metastatic castrate-resistant prostate cancer F Dayyani, GE Gallick, CJ Logothetis, PG Corn Journal of the National Cancer Institute 103 (22), 1665-1675, 2011 | 163 | 2011 |
| Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes F Dayyani, KU Belge, M Frankenberger, M Mack, T Berki, ... Journal of Leucocyte Biology 74 (1), 33-39, 2003 | 160 | 2003 |
| The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase R Schmidmaier, P Baumann, M Simsek, F Dayyani, B Emmerich, ... Blood 104 (6), 1825-1832, 2004 | 154 | 2004 |
| Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis S Holdenrieder, B Wehnl, K Hettwer, K Simon, S Uhlig, F Dayyani British journal of cancer 116 (8), 1037-1045, 2017 | 129 | 2017 |
| Transcript profiling of CD 16‐positive monocytes reveals a unique molecular fingerprint M Frankenberger, TPJ Hofer, A Marei, F Dayyani, S Schewe, C Strasser, ... European journal of immunology 42 (4), 957-974, 2012 | 117 | 2012 |
| Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias WJ Kim, RA Okimoto, LE Purton, M Goodwin, SM Haserlat, F Dayyani, ... Blood, The Journal of the American Society of Hematology 111 (9), 4716-4722, 2008 | 114 | 2008 |
| Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival F Dayyani, J Wang, JRJ Yeh, EY Ahn, E Tobey, DE Zhang, ID Bernstein, ... Blood, The Journal of the American Society of Hematology 111 (8), 4338-4347, 2008 | 109 | 2008 |
| The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials A Varkaris, PG Corn, S Gaur, F Dayyani, CJ Logothetis, GE Gallick Expert opinion on investigational drugs 20 (12), 1677-1684, 2011 | 98 | 2011 |
| Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab+ bevacizumab treatment of hepatocellular carcinoma AX Zhu, F Dayyani, CJ Yen, Z Ren, Y Bai, Z Meng, H Pan, P Dillon, ... Clinical Cancer Research 28 (16), 3537-3545, 2022 | 93 | 2022 |
| Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis F Dayyani, S Uhlig, B Colson, K Simon, V Rolny, D Morgenstern, ... International Journal of Gynecological Cancer 26 (9), 1586-1593, 2016 | 92 | 2016 |
| Clinically meaningful use of blood tumor markers in oncology S Holdenrieder, L Pagliaro, D Morgenstern, F Dayyani BioMed Research International 2016 (1), 9795269, 2016 | 87 | 2016 |
